Ke H - Search Results

1

Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.

Meng F, Hou J, Shao YX, Wu PY, Huang M, Zhu X, Cai Y, Li Z, Xu J, Liu P, Luo HB, Wan Y, Ke H. Meng F, et al. Among authors: ke h. J Med Chem. 2012 Oct 11;55(19):8549-58. doi: 10.1021/jm301189c. Epub 2012 Oct 1. J Med Chem. 2012. PMID: 22985069 Free PMC article.

2

Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

Huai Q, Sun Y, Wang H, Macdonald D, Aspiotis R, Robinson H, Huang Z, Ke H. Huai Q, et al. Among authors: ke h. J Med Chem. 2006 Mar 23;49(6):1867-73. doi: 10.1021/jm051273d. J Med Chem. 2006. PMID: 16539372 Free PMC article.

3

Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity.

Ke H, Wang H. Ke H, et al. Curr Top Med Chem. 2007;7(4):391-403. doi: 10.2174/156802607779941242. Curr Top Med Chem. 2007. PMID: 17305581 Review.

4

Structural insight into substrate specificity of phosphodiesterase 10.

Wang H, Liu Y, Hou J, Zheng M, Robinson H, Ke H. Wang H, et al. Among authors: ke h. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5782-7. doi: 10.1073/pnas.0700279104. Epub 2007 Mar 26. Proc Natl Acad Sci U S A. 2007. PMID: 17389385 Free PMC article.

5

An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.

Chen G, Wang H, Robinson H, Cai J, Wan Y, Ke H. Chen G, et al. Among authors: ke h. Biochem Pharmacol. 2008 May 1;75(9):1717-28. doi: 10.1016/j.bcp.2008.01.019. Epub 2008 Feb 12. Biochem Pharmacol. 2008. PMID: 18346713 Free PMC article.

6

Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain.

Yan Z, Wang H, Cai J, Ke H. Yan Z, et al. Among authors: ke h. Protein Expr Purif. 2009 Mar;64(1):82-8. doi: 10.1016/j.pep.2008.10.005. Epub 2008 Oct 19. Protein Expr Purif. 2009. PMID: 18984055 Free PMC article.

7

Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.

Zheng S, Kaur G, Wang H, Li M, Macnaughtan M, Yang X, Reid S, Prestegard J, Wang B, Ke H. Zheng S, et al. Among authors: ke h. J Med Chem. 2008 Dec 25;51(24):7673-88. doi: 10.1021/jm701635j. J Med Chem. 2008. PMID: 19049349 Free PMC article.

8

Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.

Wang H, Luo X, Ye M, Hou J, Robinson H, Ke H. Wang H, et al. Among authors: ke h. J Med Chem. 2010 Feb 25;53(4):1726-31. doi: 10.1021/jm901519f. J Med Chem. 2010. PMID: 20121115 Free PMC article.

9

Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.

Hou J, Xu J, Liu M, Zhao R, Luo HB, Ke H. Hou J, et al. Among authors: ke h. PLoS One. 2011 Mar 31;6(3):e18092. doi: 10.1371/journal.pone.0018092. PLoS One. 2011. PMID: 21483814 Free PMC article.

10

Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

Seebeck T, Sterk GJ, Ke H. Seebeck T, et al. Among authors: ke h. Future Med Chem. 2011 Aug;3(10):1289-306. doi: 10.4155/fmc.11.77. Future Med Chem. 2011. PMID: 21859303 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,551 results

Search Page

Filters